<DOC>
	<DOCNO>NCT00126958</DOCNO>
	<brief_summary>This randomized clinical multicentre trial aim evaluate efficacy microsatellite analysis void urine detect tumour recurrence follow-up patient superficial urothelialcell carcinoma ( UCC ) . Further , study aim identify subgroup patient low risk tumour recurrence use clinico-pathologic tumour characteristic combination genetic marker ( FGFR3 gene ) , frequency follow-up contact reduce . The overall objective reduce frequency cystoscopy follow-up patient superficial UCC , lead improvement quality life equal low cost . This study evaluate cost-effectiveness follow-up bladder cancer .</brief_summary>
	<brief_title>Cost-Effectiveness Bladder Cancer</brief_title>
	<detailed_description>The randomized clinical study consist two intervention arm . The control arm consist conventional follow-up base regular monitoring urinary bladder UCC recurrences cystoscopy . In test arm proportion cystoscopies replace microsatellite analysis void urine . Both arm stratify clinical pathological tumour parameter well mutation status prognostic FGFR3 gene mutation .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>All patient resectable pT1 pTa , grade G1G2 transitional cell carcinoma bladder biopsy proven Patients present present transitional cell carcinoma bladder , stage pT2 invasive , carcinoma situ ( CIS ) and/or G3 diagnose history</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>superficial urothelial cell carcinoma</keyword>
	<keyword>urinary analysis</keyword>
	<keyword>Loss heterozygosity</keyword>
	<keyword>FGFR3 mutation</keyword>
	<keyword>follow-up</keyword>
</DOC>